Biologicals | Drug | Covid-19 vaccines approved for use in India – What you need to know · CliniexpertsCovid-19 vaccines approved for use in India – What you need to know Indian, one of the leaders in the pharmaceutical sector, is set to play a vital role in the global COVID-19 vaccination effort.On 03 January 2021, the Drugs Controller General of India (DCGI) granted emergency approval for two COVID-19 vaccines –Covishield and Covaxin. BiologicalsPhase 1 TrialPhase 2 TrialPhase 3 TrialRegulatory CDSCO
Biologicals | Phase 2-3 Clinical Trials for Covaxin To Commence On Children Aged 2-18 Years Soon · Cliniexperts Phase 2-3 Clinical Trials for Covaxin To Commence On Children Aged 2-18 Years Soon On the 13th of May, 2021, as per one of the country’s top health officials, India’s very first trial of a domestically manufactured Covid-19 vaccine is all set to commence on children in the next 10-12 days. At the forefront Phase 2 TrialPhase 3 TrialVaccines
Biologicals | COVID-19 – Can patent waivers increase vaccine coverage? · CliniexpertsCOVID-19 – Can Patent Waivers Increase Vaccine Coverage? With the new virus variant causing a surge in infections, India has been crippled by the pandemic. Apart from the shortage of medicines, oxygen and healthcare staff, several states in India face a shortage of vaccines – one of the most effective tools to end the pandemic. Biologicals VaccinesGlobal Clinical TrialLocal Clinical TrialVaccines
Biologicals | Biosimilars in India – Things you need to know · CliniexpertsBiosimilars in India – Things you need to know Biological agents show significant clinical benefits, but their high cost limits their accessibility. The demand for cost-effective options and the patent expiry of biologics have propelled the development of biosimilars or similar biologics. This article covers the key takeaways from the Indian regulatory guidelines for the BiologicalsBlood productsrDNA ProductsRegulatory CDSCOStem cells and cell-based products
Biologicals | COVID-19 Vaccine Development: Key Developments in India · Cliniexperts COVID-19 Vaccine Development: Key Developments in India The Covid-19 emergency has propelled a race for preventive vaccines and treatment, with numerous efforts by companies, commercial consortia, and scientific organizations worldwide. India is a hub for vaccine production and produces 60 percent of the world’s vaccines. Indian companies have played a pivotal role in producing Global Clinical TrialLocal Clinical TrialRegulatory CDSCOVaccines
Biologicals | Clinical Trials For COVID-19 · Cliniexperts Clinical Trial For Coronavirus COVID-19 The COVID-19 pandemic continues to spread globally despite lockdowns and restrictions. The lack of definitive treatment for the deadly virus has propelled research towards a multipronged approach to mitigate transmission, morbidity, and mortality. In response to the global emergency, clinical trials assessing the efficacy and safety of interventions to Global Clinical TrialLocal Clinical TrialVaccines
Biologicals | Vaccines for COVID-19: Time to Fast-Track · CliniexpertsVaccines for COVID-19: Time to Fast-Track While most people are experiencing lockdown blues, scientists worldwide are working endlessly towards developing a viable vaccine for Covid-19 to knock down SARS-CoV-2, the deadly coronavirus. Research at a molecular level would help us understand the virus lifecycle and enhance our preparedness to develop strategies against SARS-CoV-2. Vaccines are Vaccines
Biologicals | Human Vaccines – Vaccines Developmental Paradigm India · CliniexpertsVaccines are one of the most beneficial and valuable disease prevention measures contributing to long-term health gains. Advancements in research have led to the development of novel vaccines and delivery technologies and this is has caused a paradigm shift in the way diseases are prevented and treated. Even though the field of vaccines have evolved Blood productsCTRIEthics CommitteePhase 1 TrialPhase 2 Trial